loading
Schlusskurs vom Vortag:
$6.89
Offen:
$7.03
24-Stunden-Volumen:
3,599
Relative Volume:
0.56
Marktkapitalisierung:
$27.77M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-24.77M
KGV:
-9.5342
EPS:
-0.73
Netto-Cashflow:
$-17.36M
1W Leistung:
-1.97%
1M Leistung:
-11.45%
6M Leistung:
-4.99%
1J Leistung:
-28.16%
1-Tages-Spanne:
Value
$6.96
$7.03
1-Wochen-Bereich:
Value
$6.89
$7.395
52-Wochen-Spanne:
Value
$4.5601
$13.79

Mink Therapeutics Inc Stock (INKT) Company Profile

Name
Firmenname
Mink Therapeutics Inc
Name
Telefon
212-994-8250
Name
Adresse
149 FIFTH AVENUE, NEW YORK
Name
Mitarbeiter
23
Name
Twitter
Name
Nächster Verdiensttermin
2024-08-13
Name
Neueste SEC-Einreichungen
Name
INKT's Discussions on Twitter

Vergleichen Sie INKT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
INKT
Mink Therapeutics Inc
6.96 28.30M 0 -24.77M -17.36M -0.73
Biotechnology icon
ONC
Beone Medicines Ltd Adr
246.68 25.81B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
447.09 111.46B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.30 40.37M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
605.39 64.44B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
77.49 6.19B 0 -153.72M -103.81M -2.00

Mink Therapeutics Inc Aktie (INKT) Neueste Nachrichten

pulisher
May 29, 2025

(INKT) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

May 29, 2025
pulisher
May 19, 2025

MiNK Therapeutics outlines near-term partnering proposals and reduced cash burn as company advances iNKT programs - MSN

May 19, 2025
pulisher
May 19, 2025

HC Wainwright Cuts Earnings Estimates for MiNK Therapeutics - Defense World

May 19, 2025
pulisher
May 16, 2025

MiNK Therapeutics, Inc. (NASDAQ:INKT) Q1 2025 Earnings Call Transcript - Insider Monkey

May 16, 2025
pulisher
May 16, 2025

MiNK Therapeutics Reports Q1 2025 Progress and Financials - TipRanks

May 16, 2025
pulisher
May 15, 2025

Mink Therapeutics’ Earnings Call Highlights Progress and Optimism - TipRanks

May 15, 2025
pulisher
May 15, 2025

Transcript : MiNK Therapeutics, Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

MiNK Therapeutics (INKT) Advances in Immune Response Innovation - GuruFocus

May 15, 2025
pulisher
May 15, 2025

MiNK Therapeutics (INKT) Advances in Immune Response Innovation | INKT Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

MiNK Therapeutics Reports Clinical Advancements and Financial Update for Q1 2025, with Focus on iNKT Cell Therapies - Nasdaq

May 15, 2025
pulisher
May 15, 2025

Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times

May 15, 2025
pulisher
May 15, 2025

MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress - GlobeNewswire

May 15, 2025
pulisher
May 11, 2025

MiNK Therapeutics (INKT) Projected to Post Earnings on Tuesday - Defense World

May 11, 2025
pulisher
May 09, 2025

Refractory Multiple Myeloma Pipeline Appears Robust With 75+ - openPR.com

May 09, 2025
pulisher
May 08, 2025

How to Take Advantage of moves in (INKT) - news.stocktradersdaily.com

May 08, 2025
pulisher
May 05, 2025

MiNK Therapeutics to Announce Q1 2025 Financial Results and Host Conference Call on May 15th - Nasdaq

May 05, 2025
pulisher
May 05, 2025

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report - GlobeNewswire

May 05, 2025
pulisher
May 05, 2025

Geode Capital Management LLC Lowers Stock Position in MiNK Therapeutics, Inc. (NASDAQ:INKT) - Defense World

May 05, 2025
pulisher
Apr 23, 2025

Learn to Evaluate (INKT) using the Charts - news.stocktradersdaily.com

Apr 23, 2025
pulisher
Apr 19, 2025

Comparing Atyr PHARMA (NASDAQ:ATYR) and MiNK Therapeutics (NASDAQ:INKT) - Defense World

Apr 19, 2025
pulisher
Apr 15, 2025

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia - Business Wire

Apr 15, 2025
pulisher
Apr 13, 2025

LIfT BioSciences appoints new CSO - Bdaily

Apr 13, 2025
pulisher
Apr 07, 2025

LIfT BioSciences Appoints Mark A. Exley as Chief Scientific Officer - EIN News

Apr 07, 2025
pulisher
Apr 07, 2025

ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch - Business Wire

Apr 07, 2025
pulisher
Apr 06, 2025

(INKT) Trading Report - news.stocktradersdaily.com

Apr 06, 2025
pulisher
Mar 30, 2025

Reviewing MiNK Therapeutics (NASDAQ:INKT) & Creative Medical Technology (NASDAQ:CELZ) - The AM Reporter

Mar 30, 2025
pulisher
Mar 27, 2025

Where are the Opportunities in (INKT) - news.stocktradersdaily.com

Mar 27, 2025
pulisher
Mar 22, 2025

HC Wainwright Issues Negative Forecast for INKT Earnings - Defense World

Mar 22, 2025
pulisher
Mar 22, 2025

What is William Blair’s Forecast for INKT Q1 Earnings? - Defense World

Mar 22, 2025
pulisher
Mar 21, 2025

What is William Blair’s Estimate for INKT Q1 Earnings? - Defense World

Mar 21, 2025
pulisher
Mar 19, 2025

MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 19, 2025
pulisher
Mar 19, 2025

MiNK Therapeutics (NASDAQ:INKT) Given Buy Rating at HC Wainwright - Defense World

Mar 19, 2025
pulisher
Mar 19, 2025

MiNK Therapeutics Inc (INKT) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada

Mar 19, 2025
pulisher
Mar 18, 2025

MiNK Therapeutics Reports 2024 Progress and Financials - TipRanks

Mar 18, 2025
pulisher
Mar 18, 2025

MiNK Therapeutics’ Earnings Call Highlights Strategic Gains - TipRanks

Mar 18, 2025
pulisher
Mar 18, 2025

MiNK Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 18, 2025
pulisher
Mar 18, 2025

Earnings call transcript: Mink Therapeutics Q4 2024 reports reduced net loss - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

Mink Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 18, 2025
pulisher
Mar 18, 2025

MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress - GlobeNewswire

Mar 18, 2025
pulisher
Mar 18, 2025

MiNK Therapeutics Reports 2024 Financial Results and Highlights Clinical Advancements in iNKT Cell Therapies - Nasdaq

Mar 18, 2025
pulisher
Mar 18, 2025

MiNK Therapeutics reports Q4 EPS (62c), consensus (50c) - TipRanks

Mar 18, 2025
pulisher
Mar 18, 2025

Earnings Scheduled For March 18, 2025 - Benzinga

Mar 18, 2025
pulisher
Mar 17, 2025

AGENUS INC SEC 10-K Report - TradingView

Mar 17, 2025
pulisher
Mar 17, 2025

(INKT) Technical Pivots with Risk Controls - Stock Traders Daily

Mar 17, 2025
pulisher
Mar 14, 2025

Mink Therapeutics Inc expected to post a loss of 50 cents a shareEarnings Preview - TradingView

Mar 14, 2025
pulisher
Mar 09, 2025

New Strong Buy Stocks for July 11th - MSN

Mar 09, 2025
pulisher
Mar 05, 2025

The Future of Refractory Multiple Myeloma Therapy: 75+ - openPR

Mar 05, 2025
pulisher
Mar 04, 2025

MiNK Therapeutics, Inc. to Announce Fourth Quarter and Year End 2024 Financial Results on March 18th - Nasdaq

Mar 04, 2025
pulisher
Mar 04, 2025

MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report - GlobeNewswire

Mar 04, 2025
pulisher
Mar 04, 2025

When Will MiNK Therapeutics Reveal Its 2024 Financial Performance? - StockTitan

Mar 04, 2025
pulisher
Feb 28, 2025

What is HC Wainwright’s Estimate for INKT Q1 Earnings? - Defense World

Feb 28, 2025

Finanzdaten der Mink Therapeutics Inc-Aktie (INKT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$1.06
price up icon 0.95%
$31.31
price up icon 3.40%
$580.95
price up icon 0.82%
$292.90
price up icon 2.57%
$4.64
price up icon 6.67%
$77.49
price up icon 4.82%
Kapitalisierung:     |  Volumen (24h):